Lazovic Biljana, Dmitrovic Radmila, Zivotic Ivan, Simonovic Isidora, Jovicic Nevena
Department of Pulmonology, University Clinical Center, Zemun, Belgrade, Serbia.
Vinča Institute of Nuclear Sciences, Belgrade, Serbia.
Tanaffos. 2024 Mar;23(3):280-286.
The neutrophil to lymphocyte ratio (NLR) is an inflammatory biomarker that could be used as an indicator of systemic inflammation (sepsis) and could also be used to predict the prognosis of some diseases, such as solid cancer, community pneumonia, as well as cardiovascular diseases. This study aimed to assess the potential role of NLR and eosinopenia in patients with acute exacerbation of COPD (AECOPD) compared to those in the stable phase of the disease.
NLR was assessed and compared in patients with AECOPD (n=92) and those in the stable phase of COPD (n=240). Patients under the age of 18, those who used inhaled corticosteroids, or those with any condition affecting the neutrophil (NEU) or lymphocyte (LYM) count in peripheral blood, such as hematological illnesses, pregnancy, or a history of medication use, were excluded from the study. The NLR was determined using NEU and LYM counts from regular blood tests. We defined the cut-off value for eosinopenia as the percentage of eosinophils≤1%.
We included 332 inpatients with COPD diagnosed in our hospital from April to October 2021. AECOPD was discovered in 92 patients. Patients with exacerbation had considerably lower levels of BMI (24.32±4.38 vs 26±4.02), FEV1/FVC (55.38±9.14 vs 60.54±6.95), and NLR ratio, except for the first NLR quartile (39.13 %), the second was 20.65 %, the third was 18.48 %, and the fourth was 21.74 %. Eosinopenia was detected in 79 (85.87 %) of AECOPD patients.
We found that the NLR was lower in patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD), except for those in the first NLR quartile.
中性粒细胞与淋巴细胞比值（NLR）是一种炎症生物标志物，可作为全身炎症（脓毒症）的指标，也可用于预测某些疾病的预后，如实体癌、社区获得性肺炎以及心血管疾病。本研究旨在评估与慢性阻塞性肺疾病（COPD）稳定期患者相比，NLR和嗜酸性粒细胞减少在慢性阻塞性肺疾病急性加重期（AECOPD）患者中的潜在作用。
对92例AECOPD患者和240例COPD稳定期患者的NLR进行评估和比较。年龄小于18岁、使用吸入性糖皮质激素的患者，或患有任何影响外周血中性粒细胞（NEU）或淋巴细胞（LYM）计数的疾病（如血液系统疾病、妊娠或用药史）的患者被排除在研究之外。通过常规血液检测中的NEU和LYM计数来确定NLR。我们将嗜酸性粒细胞减少的临界值定义为嗜酸性粒细胞百分比≤1%。
我们纳入了2021年4月至10月在我院诊断为COPD的332例住院患者。其中92例患者被诊断为AECOPD。急性加重期患者的体重指数（BMI）（24.32±4.38 vs 26±4.02）、第1秒用力呼气容积占用力肺活量的比值（FEV1/FVC）（55.38±9.14 vs 60.54±6.95）和NLR比值显著较低，除了第一个NLR四分位数（39.13%），第二个为20.65%，第三个为18.48%，第四个为21.74%。79例（85.87%）AECOPD患者检测到嗜酸性粒细胞减少。
我们发现，除了处于第一个NLR四分位数的患者外，慢性阻塞性肺疾病急性加重期（AECOPD）患者NLR较低。
